Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
Pfizer is navigating a complex transition defined by a massive post-COVID revenueRevenueRevenue is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions. cliff and impending Loss of Exclusivity (LOE) for several key blockbusters (e.g., Eliquis, Ibrance). While the stock offers an attractive 6.7% dividend yieldDividend yieldTrailing or indicated annual dividend divided by share price. The cash income return on equity, before any capital appreciation or buybacks., the payout is precariously covered by current Free Cash FlowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics.. The thesis depends on Pfizer's ability to seamlessly integrate the Seagen acquisition, execute on its internal pipeline, and realize billions in cost savings to stabilize margins and defend the dividend.
A stress test applying zero terminal growthTerminal growthThe perpetual growth rate assumed in the Gordon-growth terminal-value calculation. Capped below long-run nominal GDP (typically 2.5–3.0% for developed-market firms). and peak generic erosion reduces fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. below $24. The $64B debt load and 130%+ payout ratioPayout ratioDividends per share divided by EPS. Measures how much of earnings the company distributes versus retains for reinvestment. leave zero margin for error in FCFFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics. generation.
FCF deteriorates further as generic competition accelerates, forcing a dividend cut to service the $64B debt load.
The $43B Seagen acquisition fails to deliver anticipated oncology synergies and revenue targets, leaving a permanent growth void.
High failure rates in late-stage clinical trials prevent replacement of the Eliquis and Ibrance revenue cliffs.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $81.29B | $101.18B+24.5% | $59.55B-41.1% | $63.63B+6.9% | $62.58B-1.7% | -6.3% |
| Gross profit | $50.47B | $66.83B | $34.60B | $45.78B | $46.51B | -2.0% |
| Operating income | $20.24B | $37.16B | $4.22B | $14.83B | $15.79B | -6.0% |
| Net income | $21.98B | $31.37B+42.7% | $2.12B-93.2% | $8.03B+278.8% | $7.77B-3.2% | -22.9% |
| EPS (diluted) | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 | -22.9% |
| EBITDA | $30.79B | $41.03B | $9.56B | $18.13B | $16.78B | -14.1% |
| R&D | $13.83B | $12.38B | $10.87B | $10.93B | $12.05B | -3.4% |
| SG&A | $12.70B | $13.68B | $14.77B | $14.73B | $13.79B | +2.1% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
